SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Phrontline Biopharma Reports Preliminary TJ101 Activity and Phase Ib Start

Phrontline Biopharma reported preliminary responses in 6 of 8 evaluable urothelial carcinoma patients and announced initiation of Phase Ib. The available body text is truncated.

SquawkNews Desk

Related stories

AstraZeneca CEO Sees Over $20 Billion in Potential Sales From 2027 Trial Readouts CEO Pascal Soriot said 2027 drug trial readouts could generate over $20 billion in peak annual sales. The company also unveiled a restructuring program targeting $1.5 billion in an M impact | EQUITY | Oct 30, 2026, 11:38 AM UTC Cboe Global Markets Reports Third-Quarter Results Cboe Global Markets reported third-quarter diluted EPS of $4.08, up 43 percent. M impact | EQUITY | Oct 30, 2026, 11:33 AM UTC Hinduja Housing Finance Appoints Vivek Kannan CEO Kannan succeeds Sachin Pillai and will oversee business performance, operations, risk and growth. He previously served as the company’s chief operating officer. M impact | EQUITY | Oct 30, 2026, 11:32 AM UTC Acumen Pharmaceuticals shares fall 75% premarket Acumen Pharmaceuticals (ABOS) shares fell 75% before the market open. H impact | EQUITY | Oct 30, 2026, 11:31 AM UTC Asian Stocks Fall, Led by South Korea’s Kospi Japan’s Nikkei 225 dropped 2.1% to 63,290.11, the Topix fell 1%, South Korea’s Kospi declined around 3.5%, and mainland China’s Shanghai Composite was down 1.4%. Semiconductor manu M impact | EQUITY | Oct 30, 2026, 11:31 AM UTC Federal Realty Reports Third-Quarter Revenue of $339M M impact | EQUITY | Oct 30, 2026, 11:30 AM UTC